Publications by authors named "Jay Powers"

Claim this Profile
D
Discovery and Characterization of Potent, Selective, and Orally Bioavailable 7-Azaindazole AXL Receptor Tyrosine Kinase Inhibitors.
Corinne N Foley, Shiwei Qu, Srinivas Reddy Paladugu, Manjunath Lamani, Rebecca Grange, Jay P Powers

J Med Chem· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of AB801, a Potent and Selective Inhibitor of AXL Receptor Tyrosine Kinase for Use in Cancer Therapy.
Dillon H Miles, Manjunath Lamani, Srinivas Reddy Paladugu, Shiwei Qu, Corinne N Foley, Jay P Powers

J Med Chem· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stereodivergent Synthesis of the Vicinal Difluorinated Tetralin of Casdatifan Enabled by Ru-Catalyzed Transfer Hydrogenation.
Guillaume Mata, Artur K Mailyan, Jeremy Fournier, Joel W Beatty, Manmohan R Leleti, Jay P Powers

Org Lett· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity.
Dana Piovesan, Joanne B L Tan, Annette Becker, Jesus Banuelos, Nell Narasappa, Jay P Powers

Mol Cancer Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, Synthesis, and Structure-Activity Relationship Optimization of Pyrazolopyrimidine Amide Inhibitors of Phosphoinositide 3-Kinase γ (PI3Kγ).
Guillaume Mata, Dillon H Miles, Samuel L Drew, Jeremy Fournier, Kenneth V Lawson, Jay P Powers

J Med Chem· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors.
Ehesan U Sharif, Jaroslaw Kalisiak, Kenneth V Lawson, Dillon H Miles, Eric Newcomb, Jay P Powers

J Med Chem· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39.
Jenna L Jeffrey, Kenneth V Lawson, Jay P Powers

J Med Chem· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Potent and Selective 7-Azaindole Isoindolinone-Based PI3Kγ Inhibitors.
Dillon H Miles, Xuelei Yan, Rhiannon Thomas-Tran, Jeremy Fournier, Ehesan U Sharif, Jay P Powers

ACS Med Chem Lett· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of AB680: A Potent and Selective Inhibitor of CD73.
Kenneth V Lawson, Jaroslaw Kalisiak, Erick A Lindsey, Eric T Newcomb, Manmohan Reddy Leleti, Jay P Powers

J Med Chem· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Potent and Selective PI3Kγ Inhibitors.
Samuel L Drew, Rhiannon Thomas-Tran, Joel W Beatty, Jeremy Fournier, Kenneth V Lawson, Jay P Powers

J Med Chem· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73.
Joel W Beatty, Erick A Lindsey, Rhiannon Thomas-Tran, Laurent Debien, Debashis Mandal, Jay P Powers

J Med Chem· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers.
Lisa Seitz, Lixia Jin, Manmohan Leleti, Devika Ashok, Jenna Jeffrey, Jay P Powers

Invest New Drugs· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.
Pirow Bekker, Daniel Dairaghi, Lisa Seitz, Manmohan Leleti, Yu Wang, Jay Powers

PLoS One· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.
Pirow Bekker, Daniel Dairaghi, Lisa Seitz, Manmohan Leleti, Yu Wang, Jay Powers

PLoS One· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CCR9 Antagonists in the Treatment of Ulcerative Colitis.
Pirow Bekker, Karen Ebsworth, Matthew J Walters, Robert D Berahovich, Linda S Ertl, Jay P Powers

Mediators Inflamm· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associate kinase-4.
Zhulun Wang, Daqing Sun, Sheree Johnstone, Zhaodan Cao, Xiong Gao, Jay P Powers

Bioorg Med Chem Lett· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis, in Vitro Covalent Binding Evaluation, and Metabolism of (14)C-Labeled Inhibitors of 11β-HSD1.
Daqing Sun, Qiuping Ye, Xuelei Yan, Yosup Rew, Peter Fan, Jay P Powers

ACS Med Chem Lett· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
C5a receptor (CD88) blockade protects against MPO-ANCA GN.
Hong Xiao, Daniel J Dairaghi, Jay P Powers, Linda S Ertl, Trageen Baumgart

J Am Soc Nephrol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.
Timothy J Sullivan, Zhenhua Miao, Bin N Zhao, Linda S Ertl, Yu Wang, Jay P Powers

Metabolism· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice.
Timothy Sullivan, Zhenhua Miao, Daniel J Dairaghi, Antoni Krasinski, Yu Wang, Jay Powers

Am J Physiol Renal Physiol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational design and binding mode duality of MDM2-p53 inhibitors.
Felix Gonzalez-Lopez de Turiso, Daqing Sun, Yosup Rew, Michael D Bartberger, Hilary P Beck, Jay P Powers

J Med Chem· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CCR9 inhibition does not interfere with the development of immune tolerance to oral antigens.
Matthew J Walters, Karen Ebsworth, Timothy J Sullivan, Penglie Zhang, Jay P Powers

Immunol Lett· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.
Daniel J Dairaghi, Babatunde O Oyajobi, Anjana Gupta, Brandon McCluskey, Shichang Miao, Jay P Powers

Blood· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and optimization of benzenesulfonanilide derivatives as a novel class of 11β-HSD1 inhibitors.
Yosup Rew, Michael DeGraffenreid, Xiao He, Juan C Jaen, Dustin L McMinn, Jay P Powers

Bioorg Med Chem Lett· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of amide replacements that improve activity and metabolic stability of a bis-amide smoothened antagonist hit.
Matthew L Brown, Wade Aaron, Richard J Austin, Angela Chong, Tom Huang, Jay P Powers

Bioorg Med Chem Lett· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis